The Effect of Pregabalin Given Preoperatively on the Tourniquet Induced Ischemia-reperfusion
Primary Purpose
Ischemia Reperfusion Injury
Status
Completed
Phase
Phase 4
Locations
Turkey
Study Type
Interventional
Intervention
Pragabalin
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Ischemia Reperfusion Injury focused on measuring pregabalin, ischemia reperfusion injury, muscle
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) physical status I-II
- Undergoing a total knee arthroplasty surgery
- Accept neuroaxial anesthesia for surgery
Exclusion Criteria:
- Any antiepileptic drug use
- Allergic reaction to pregabalin
- Severe hepatic, renal or gastrointestinal disorders
- Psychiatric disorders
- Pregnant women or breastfeeding
- NSAID or opioid drug use for a long time
- Diabetic or other neuropathic pain
Sites / Locations
- Baskent University
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Pregabalin Group
Control Group
Arm Description
We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
Outcomes
Primary Outcome Measures
ischemia modified albumin
changes of ischemia modified albumin
total oxidant status
changes of total oxidant status
total antioxidant status
changes of total antioxidant status
Secondary Outcome Measures
catalase
changes of catalase
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03482544
Brief Title
The Effect of Pregabalin Given Preoperatively on the Tourniquet Induced Ischemia-reperfusion
Official Title
Effect of Orally Pregabalin Given Before Knee Joint Replacement on Reperfusion Injury Which Caused by Bandage
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
October 10, 2018 (Actual)
Primary Completion Date
October 30, 2018 (Actual)
Study Completion Date
November 15, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baskent University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The application of tourniquet is indispensable for a bloodless surgical area in total knee arthroplasty surgery. The release of tourniquet produces reactive oxygen species which can cause injury and then ischemia-reperfusion injury emerge. Our aim in this study is to investigate effects of pregabalin, GABA analog drug, on the tourniquet induced ischemia-reperfusion injury.
Detailed Description
Investigators will randomize patients into two groups. 1) Pregabalin group 2) Control group.
Investigators will give orally pregabalin 150 mg to the pregabalin group patients two times (first dose 1 day before surgery., second dose 1 hour before surgery). On the other hand placebo drug will give to the control group at the same times. Investigators will perform combined spinal epidural anesthesia for surgery and inject 3 cc 0.5% hyperbaric bupivacaine to subarachnoid space. Investigators will take blood samples for measurement of ischemia-reperfusion determinants, immediately before surgery, shortly before tourniquet deflation, and 20 minutes after tourniquet deflation. Then these samples will be analysed by ELISA method.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemia Reperfusion Injury
Keywords
pregabalin, ischemia reperfusion injury, muscle
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
54 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pregabalin Group
Arm Type
Active Comparator
Arm Description
We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
Intervention Type
Drug
Intervention Name(s)
Pragabalin
Other Intervention Name(s)
pregabalin 150 mg, Lyrica, Pfezir, Almanya
Intervention Description
pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
empty capsule
Intervention Description
empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
Primary Outcome Measure Information:
Title
ischemia modified albumin
Description
changes of ischemia modified albumin
Time Frame
before tournique application,just before tournique release, 20 minutes after tournique release
Title
total oxidant status
Description
changes of total oxidant status
Time Frame
before tournique application, just before tournique release, 20 minutes after tournique release
Title
total antioxidant status
Description
changes of total antioxidant status
Time Frame
before tournique application, just before tournique release, 20 minutes after tournique release
Secondary Outcome Measure Information:
Title
catalase
Description
changes of catalase
Time Frame
before tournique application, just before tournique release, 20 minutes after tournique release
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists (ASA) physical status I-II
Undergoing a total knee arthroplasty surgery
Accept neuroaxial anesthesia for surgery
Exclusion Criteria:
Any antiepileptic drug use
Allergic reaction to pregabalin
Severe hepatic, renal or gastrointestinal disorders
Psychiatric disorders
Pregnant women or breastfeeding
NSAID or opioid drug use for a long time
Diabetic or other neuropathic pain
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Omer Karaca, Assist.Prof
Organizational Affiliation
Baskent University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baskent University
City
Konya
Country
Turkey
12. IPD Sharing Statement
Citations:
PubMed Identifier
8528679
Citation
Davies SJ, Reichardt-Pascal SY, Vaughan D, Russell GI. Differential effect of ischaemia-reperfusion injury on anti-oxidant enzyme activity in the rat kidney. Exp Nephrol. 1995 Nov-Dec;3(6):348-54.
Results Reference
background
PubMed Identifier
26380243
Citation
Vafapour M, Nematbakhsh M, Monajemi R, Mazaheri S, Talebi A, Talebi N, Shirdavani S. Effect of Gamma-aminobutyric acid on kidney injury induced by renal ischemia-reperfusion in male and female rats: Gender-related difference. Adv Biomed Res. 2015 Jul 27;4:158. doi: 10.4103/2277-9175.161585. eCollection 2015.
Results Reference
background
PubMed Identifier
26941907
Citation
Talebi N, Nematbakhsh M, Monajemi R, Mazaheri S, Talebi A, Vafapour M. The Protective Effect of gamma-aminobutyric Acid on Kidney Injury Induced by Renal Ischemia-reperfusion in Ovariectomized Estradiol-treated Rats. Int J Prev Med. 2016 Jan 11;7:6. doi: 10.4103/2008-7802.173796. eCollection 2016.
Results Reference
background
Learn more about this trial
The Effect of Pregabalin Given Preoperatively on the Tourniquet Induced Ischemia-reperfusion
We'll reach out to this number within 24 hrs